Current Opinion in Lipidology
Oral PCSK9 inhibitors: closing the gap between potency and practicality
ReviewInterventions
Papers by Ann Marie Navar
11 results
- Nature Reviews Nephrology
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
ReviewInterventions - Journal of the American College of Cardiology
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a)
Randomised trial in 213 peopleInterventions - Circulation Population Health and Outcomes
Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry
Study in peoplePopulations
- Journal of the American College of Cardiology
Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults
Cross-sectional study in peopleIndustry & policy - ADA Scientific Sessions 2026 Abstract
Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials
Trial in peopleInterventions - AHA Scientific Sessions 2025 Abstract
Treatment Implications of LDL-Cholesterol and Apolipoprotein B Discordance: Insights from the Very Large Database of Lipids (VLDbL) and the National Health and Examination Survey (NHANES)
Study in peopleBiomarkers - AHA Scientific Sessions 2025 Abstract
Not All LDLs are Created Equal: Discordance Between Calculated LDL-C Estimates and Incident ASCVD in the Multi-Ethnic Study of Atherosclerosis
Study in peopleBiomarkers - AHA Scientific Sessions 2025 Abstract
Discrimination in Healthcare and Incident Stroke or Myocardial Infarction
Study in peoplePopulations - AHA Scientific Sessions 2025 Abstract
Longitudinal LDL-C Control Among Patients With ASCVD and Elevated Baseline LDL-C: Insights From the cvMOBIUS-2 Registry
Study in peoplePopulations